Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Could Drones Delivering Defibrillators Save Lives?Statins Going Generic Saved Medicare BillionsAHA News: Looming Wave of Evictions, Housing Instability Pose Threat to HealthAHA News: Health Apps Pose Privacy Risks, But Experts Offer This AdviceCould You Save a Life After Mass Violence? Most Americans Say NoGun Violence Costs U.S. Health Care System $170 Billion AnnuallyWith COVID Vaccine in Works, 1 in 5 Americans Doesn't Believe in ShotsTelehealth Skyrocketing Among Older AdultsPharmacists in All U.S. States Can Give Kids Childhood ShotsAHA News: COVID-19's Economic Fallout Expands Food Insecurity, as Groups Scramble to HelpCOVID-19 Clinical Trials Lack Diversity, Researchers SayLook Beyond Fossil Fuels to Curb Air PollutionTelemedicine Is Here: Experts Offer Tips for SeniorsMany Older Adults Can't Connect With Telehealth: StudyAHA News: High-Speed Internet Offers Key Connection to Health, But Millions Lack It11 States Could Face ICU Doc Shortages as Coronavirus Cases SurgeWill the Telemedicine Boom Outlast the Pandemic?Yet Another Study Finds Vaccines Are SafeIn Rush to Publish, Most COVID-19 Research Isn't Reliable, Experts SayWith Tighter Handgun Laws, U.S. Would See Fewer Suicides by Young PeoplePandemic Has ER Docs Stressed Out and Weary: SurveyU.S. Air Quality Got Better During Pandemic: StudyColon Cancer Tests by Mail Might Boost ScreeningWill CPR Save Your Life? Study Offers a Surprising AnswerWill COVID Pandemic's Environmental Benefit Last?AHA News: As Pandemic Disrupts Research, Scientists Look for New Ways ForwardAmericans Lag Behind Brits When It Comes to HealthBan Menthol Cigarettes, Lower Smoking Rates?Tech Is Keeping More Americans in Touch With DoctorsEven Small Reductions in Air Pollution Help The HeartHigh Costs Lead Millions of Americans to Shop Abroad for Rx DrugsPandemic Hits Primary Care Practices Hard Across the U.S.: StudyOne-Time Treatment Eases Parkinson's -- in MiceAHA News: Here's What Doctors Know About Immunizations Right Now – You Still Need ThemDoctors' Choice of Anesthesia Could Help Curb Climate ChangeTough State Gun Laws Help Save Lives: StudyBlood Donors Will Get Results of Coronavirus Antibody Test, Red Cross SaysCOVID Got You Scared of Performing CPR? Study Finds Infection Risk Is LowFor Stressed-Out Black Americans, Mental Health Care Often Hard to Come ByHealthDay In-Depth
The AI Revolution: For Patients, Promise and Challenges Ahead">HealthDay In-Depth
The AI Revolution: For Patients, Promise and Challenges Ahead
Women Still Left Out of Much Medical ResearchHealthDay In-Depth
The AI Revolution: Robots Already Helping Humans Deliver Better Care">HealthDay In-Depth
The AI Revolution: Robots Already Helping Humans Deliver Better Care
HealthDay In-Depth
The AI Revolution: Giving Docs a Diagnostic Assist">HealthDay In-Depth
The AI Revolution: Giving Docs a Diagnostic Assist
AHA News: Calorie Data on Menus Could Generate Significant Health, Economic BenefitsPandemic Has Left Nearly 43 Million Americans Without WorkPeople Are Avoiding the ER During COVID-19 Crisis at Their Peril: StudyAs Postponed Surgeries Resume, Can U.S. Hospitals Handle the Strain?Most Americans Still More Worried About COVID-19 Spread Than the EconomyBig Need for Blood Donations as Postponed Surgeries ResumeEmergency Transport Can Surprise Many With Big Bills
Links
Related Topics

Health Insurance
Healthcare

COVID-19 Clinical Trials Lack Diversity, Researchers Say

HealthDay News
by -- Steven Reinberg
Updated: Aug 17th 2020

new article illustration

MONDAY, Aug. 17, 2020 (HealthDay News) -- Although minorities are paying a disproportionate price in the rate of COVID-19 illnesses and deaths, they are underrepresented in clinical trials, a new study finds.

The researchers call upon the government, medical journals and funders of research to make sure trials include minorities so that the results can be extrapolated to the U.S. population.

In the Adaptive COVID-19 Treatment Trial involving more than 1,000 patients testing the efficacy of the antiviral remdesivir, only 20% of participants are Black and 23% are Hispanic or Native American.

In the clinical trial funded by the drug's maker, Gilead, with nearly 400 patients, only 11% are Black and less than 1% are Hispanic or Native American.

"The overwhelming majority of the patients in both of those large clinical trials were Caucasians," said researcher Daniel Chastain, a clinical assistant professor of pharmacy at the University of Georgia's Albany campus.

"Knowing that African Americans die at a higher rate than Caucasians, can I say that this medication will work in them as well? Yes, they enrolled a bunch of patients and yes they got these data out as fast as possible, but can we use this information to inform treatments in all patients?" he said in a university news release.

The remdesivir trials found that patients given the drug recovered from COVID-19 a little faster than those given a placebo. But minority patients often have more severe symptoms and complications from the disease, so it's not clear if they will respond as well to the drug.

"Why aren't we putting up infrastructure for clinical trial sites in areas that were heavily hit by COVID?" Chastain said. "If we would've included Albany, those clinical trials would've been more diversified and would've been much more representative of what the coronavirus pandemic looks like in our area and throughout the U.S."

The report was published Aug. 12 in the New England Journal of Medicine.

More information

For more on COVID-19, head to the U.S. Centers for Disease Control and Prevention.




328 W. Claiborne St.
P.O. Box 964
Monroeville,
Alabama 36460
Tel: (251)575-4203
Fax:(251)575-9459


powered by centersite dot net